Trials / Completed
CompletedNCT00051662
Safety, Efficacy and Pharmacokinetics of an Antibody for Psoriatic Arthritis
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Safety, Efficacy and Pharmacokinetics of Efalizumab in Subjects With Psoriatic Arthritis
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 45 (planned)
- Sponsor
- XOMA (US) LLC · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether a humanized monoclonal antibody (efalizumab) is safe and effective in the treatment of psoriatic arthritis (PsA)
Detailed description
A phase II, randomized, double-blind, placebo-controlled study to: 1. Demonstrate the clinical efficacy of efalizumab in the treatment of subjects with psoriatic arthritis (PsA). 2. Evaluate the safety, tolerability and pharmacokinetics of efalizumab in the treatment of subjects with PsA
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | efalizumab |
Timeline
- Completion
- 2004-02-01
- First posted
- 2003-01-16
- Last updated
- 2005-06-24
Source: ClinicalTrials.gov record NCT00051662. Inclusion in this directory is not an endorsement.